Venclexta for Chronic Lymphocytic Leukemia (with 17p deletion) – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Withdrawn |
PC0087-000 |
EtanerceptOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SE0513-000 |
BrexpiprazoleOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0514-000 |
abobotulinumtoxinAOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0512-000 |
Darzalex for Multiple Myeloma – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0079-000 |
Afinitor for Neuroendocrine tumors of Gastrointestinal or Lung origin – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0083-000 |
EliglustatOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0511-000 |
Glatiramer acetateOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SE0510-000 |
Single Drug Technology Assessment Processes Across Health Technology Assessment OrganizationsOpens in new tab |
|
|
|
Health Technology Review |
Environmental Scan |
Completed |
ES0293-000 |
Ibrance for Advanced Breast Cancer Resubmission – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0093-000 |
Onivyde for Metastatic Pancreatic Cancer (Closed) Opens in new tab |
|
|
|
Reimbursement Review |
|
Cancelled |
PC0096-000 |
Obeticholic AcidOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0509-000 |
Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0077-000 |
Imbruvica for Chronic Lymphocytic Leukemia (previously untreated) – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0085-000 |
Imbruvica for Waldenström’s Macroglobulinemia - DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0082-000 |
Kyprolis (with lenalidomide) for Multiple Myeloma – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0067-000 |
emtricitabine/rilpivirine/ tenofovir alafenamideOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0507-000 |
Daclizumab betaOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0508-000 |
Lynparza for Ovarian Cancer (2nd line) – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0081-000 |
Zydelig for Follicular Lymphoma – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0075-000 |
IvabradineOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0506-000 |
Lenvima for Differentiated Thyroid Cancer – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0080-000 |
LiraglutideOpens in new tab |
|
|
|
Reimbursement Review |
|
Withdrawn |
SR0505-000 |
Opdivo for Metastatic Renal Cell Carcinoma – DetailsOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
PC0074-000 |
SarilumabOpens in new tab |
|
|
|
Reimbursement Review |
|
Complete |
SR0503-000 |